BCHE and Cognitive impairment: In addition, all participants on this study were on cholinesterase inhibitor therapy, which was a deliberate inclusion criterion to make the data relevant to the clinical situation for individuals with mild cognitive impairment, and to account for potential pharmacokinetic interactions with the CAW components.